Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53. People with myelofibrosis (MF) who undergo hematopoietic stem cell transplantation ...

Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial. “New novel therapies ...

In a recent study published in Nature Genetics, researchers performed an allelic-level single-cellular multi-omics evaluation of hematopoietic stem/progenitor cells (HSPCs) obtained from individuals ...

The TP53 gene provides instructions for making a protein called tumor protein p53 (or p53). This protein regulates cell division by keeping cells from growing and dividing too fast or in an ...

TP53 aberrations have been used as prognostic markers and can inform treatment decision making for patients with CLL. TP53 aberrations should be assessed prior to each treatment decision, according to ...

—A study of 1230 individuals with chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis demonstrated that patients with wild type TP53 had longer time to first treatment and ...

Men who have mutations in a gene called TP53 have a high risk of developing aggressive prostate cancer, a multicenter research team in the United States has found. The findings were reported in the ...

PHILADELPHIA -- (Jan. 24, 2020) -- In a study by The Wistar Institute and collaborators, a rare, African-specific variant of the TP53 gene called P47S causes iron accumulation in macrophages and other ...

Drugging the Master Regulator TP53 in Cancer: Mission Possible? The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated ...

PHILADELPHIA - Rare inherited mutations in the body's master regulator of the DNA repair system - the TP53 gene - can leave people at a higher risk of developing multiple types of cancer over the ...